Open AccessPeritoneal metastases of colorectal origin treated by cytoreduction and HIPEC: An overview
Author(s) -
Álvaro ArjonaSánchez,
Francisco Javier Burón Fernández,
F.C. Muñoz-Casares,
Ángela Casado-Adam,
Juan Manuel Sánchez-Hidalgo,
Sebastián Rufián-Peña
Publication year - 2014
Publication title -
world journal of gastrointestinal oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.924
H-Index - 26
ISSN - 1948-5204
DOI - 10.4251/wjgo.v6.i10.407
Subject(s) - medicine , hyperthermic intraperitoneal chemotherapy , peritoneal carcinomatosis , cytoreductive surgery , colorectal cancer , chemotherapy , surgery , intraperitoneal chemotherapy , oncology , general surgery , cancer , ovarian cancer
Colorectal peritoneal carcinomatosis was considered a terminal condition with a merely palliative treatment that included only supportive care, palliative surgery and the best systemic chemotherapy. Since the birth of a new approach, cytoreductive surgery with peritonectomy procedures together with hyperthermic intraperitoneal chemotherapy and/or early postoperative intraperitoneal chemotherapy to treat peritoneal carcinomatosis, many research groups contributed with promising results using this procedure being up to date this strategy the only one that has shown curative benefits on colorectal peritoneal carcinomatosis achieving reported overall survival rates up to 64 mo and five-year survival rates up to 51%. The aim of this paper is to expose an updated overview of the therapeutic possibilities of these procedures in colorectal peritoneal metastases in the same way that our Unit of Oncologic Surgery has performed since 1997 with more than four hundred procedures.